Search
Diabetes News

FDA Approves Bristol-Myers Drug for Rare Body Fat Disorder

Posted by dlife on Wed, Feb 26, 14, 01:51 PM 0 Comment

February 26, 2014 (Reuters) — The U.S. Food and Drug Administration said it approved Bristol-Myers Squibb Co's drug to treat rare and potentially fatal disorders involving loss of body fat.

The drug has been approved as a replacement therapy to treat complications caused by leptin hormone deficiency in patients with congenital or acquired generalized lipodystrophy.

Generalized lipodystrophy patients experience a loss of fat tissue, especially under the skin, leading to low levels of leptin.

Leptin deficiency causes serious imbalance in the body, leading to fat accumulation in muscles and organs such as the liver. The deficiency can lead to diabetes, pancreatitis and fatty liver disease.

The drug, Myalept (metreleptin), is a form of leptin meant to reduce accumulation of fat in organs to better control blood sugar and high levels of triglycerides - a type of fat in the bloodstream associated with increased risk of heart disease.

The FDA said it asked for seven post-marketing studies on Myalept. (r.reuters.com/jam27v)

Bristol-Myers had co-developed the drug with AstraZeneca.

Email this

Sign up for FREE dLife Newsletters

dLife Membership is FREE! Get exclusive access, free recipes, newsletters, savings, and much more! FPO

Congratulations!
You are subscribed!
Congratulations!
You are subscribed!
Congratulations!
You are subscribed!
Sponsor Specials

dLife Weekly Poll

If you are a parent with diabetes, do you find that diabetes gets in the way of your parenting?